Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;80(10):1019-1025.
doi: 10.1007/s40265-020-01337-5.

Sacituzumab Govitecan: First Approval

Yahiya Y Syed  1
Affiliations
Review

Sacituzumab Govitecan: First Approval

Yahiya Y Syed. Drugs. 2020 Jul.

Abstract

Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the USA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Sacituzumab govitecan is undergoing phase III development for breast cancer in the USA and EU, and phase II development for urothelial cancer. It is also being explored for brain metastases, glioblastoma, endometrial cancer and prostate cancer. This article summarizes the milestones in the development of sacituzumab govitecan leading to this first approval for mTNBC.

PubMed Disclaimer

Conflict of interest statement

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Figures

None
Key milestones in the development of sacituzumab govitecan, focusing on breast cancer. BLA Biologics License Application, mTNBC metastatic triple-negative breast cancer, Est estimated
None
Chemical structure of sacituzumab govitecan
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Immunomedics. Advanced antibody-based therapeutics [presentation]. 2017. https://www.immunomedics.com. Accessed 20 May 2020.
    1. Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (Trop-2) as a novel cancer target. Oncotarget. 2018;9(48):28989–29006. doi: 10.18632/oncotarget.25615. - DOI - PMC - PubMed
    1. Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) Oncotarget. 2015;6(26):22496–22512. doi: 10.18632/oncotarget.4318. - DOI - PMC - PubMed
    1. Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjugate Chem. 2015;26(5):919–931. doi: 10.1021/acs.bioconjchem.5b00223. - DOI - PubMed
    1. Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer-xenograft models and monkeys. Clin Cancer Res. 2011;2011:clincanres.2939.010. - PMC - PubMed

MeSH terms